arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ginkgo Bioworks Holdings, Inc.

DNA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$7.93
▲ +1.5% Today
as of Jul 22, 16:48 ET
Last 30 days -4.86% Jun 15 → Jul 22
$7.32 $8.15 $8.97 $9.80 $10.63 Jun 15 Jun 23 Jun 30 Jul 08 Jul 15 Jul 22
Open
$8.90
High
$8.98
Low
$7.94
Volume
$1M
Avg Vol
$1M
Mkt Cap
$469M
P/E (TTM)
—
Beta
—
52w High
$17.58
52w Low
$5.37
Div Yield
—
Shares Out
$62M

Recent Press Releases & News last 60 days · 1 item

May 26 · 16:33 PR PR Newswire
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Overview

52-week range
$5.37
$18
21% of range
Avg surprise (last 2)
-2.4%
Avg reaction (last 2)
-2.2%
50% positive
Latest IV / EM
102%
EM ±23.4% · $8 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-6.21$-4.68$-3.15$-1.62$-0.09 Actual $-0.09Actual $-6.21Actual $-3.32Actual $-4.23Actual $-1.08Actual $-1.58Est $-1.23Actual $-1.10Est $-1.44Actual $-1.45Actual $-1.28 JunSepMarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-217M$-140M$-62M$16M$93M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu May 7, 2026Mar/2026 $-1.28 — — +19.0% +2.4% earnings
Tue Sep 30, 2025Sep 2025 $-1.45 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.10 $-1.44 +23.6% — — earnings
Tue May 6, 2025Mar/2025 $-1.58 $-1.23 -28.5% — -6.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.08 — — — — financials
Sun Jun 30, 2024Jun 2024 $-4.23 — — — — financials
Sun Mar 31, 2024Mar 2024 $-3.32 — — — — financials
Sat Sep 30, 2023Sep 2023 $-6.21 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.09 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Aug 6, 2026Jun/2026OTHER —-$1.10

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$19M—$39M$50M$38M—$89M$56M
Cost of revenue$3M———$4M———
Gross profit————————
Operating income$-71M—$-90M$-66M$-81M—$-55M$-223M
Net income$-83M—$-81M—$-91M—$-56M$-217M
EPS (diluted)——$-1.45$-1.10$-1.68—$-1.08$-4.23

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$144M$167M$111M$204M$312M$562M$616M$730M
Inventory————————
Total current assets$410M$472M$506M$523M$565M$603M$662M$783M
Total assets$1.03B$1.12B$1.19B$1.23B$1.29B$1.38B$1.48B$1.63B
Long-term debt————————
Total liabilities$590M$611M$629M$618M$646M$661M$683M$792M
Total equity$443M$509M$560M$613M$647M$716M$798M$833M

Implied volatility — last 90 days

93%135%176%218%259% Jun 07 — IV 132% · EM ±18.2%Jun 08 — IV 115% · EM ±15.1%Jun 09 — IV 113% · EM ±14.1%Jun 10 — IV 120% · EM ±14.2%Jun 11 — IV 119% · EM ±13.1%Jun 12 — IV 102% · EM ±10.5%Jun 15 — IV 109% · EM ±7.9%Jun 16 — IV 129% · EM ±7.6%Jun 17 — IV 210% · EM ±8.8%Jun 19 — IV 95% · EM ±21.0%Jun 22 — IV 98% · EM ±20.5%Jun 23 — IV 94% · EM ±19.2%Jun 24 — IV 105% · EM ±21.1%Jun 25 — IV 96% · EM ±18.8%Jun 26 — IV 94% · EM ±18.0%Jun 29 — IV 100% · EM ±17.6%Jun 30 — IV 101% · EM ±17.4%Jul 01 — IV 102% · EM ±17.0%Jul 02 — IV 97% · EM ±15.6%Jul 03 — IV 98% · EM ±15.4%Jul 06 — IV 107% · EM ±14.8%Jul 07 — IV 96% · EM ±12.7%Jul 08 — IV 108% · EM ±13.5%Jul 09 — IV 109% · EM ±12.9%Jul 10 — IV 109% · EM ±12.1%Jul 13 — IV 107% · EM ±9.0%Jul 14 — IV 130% · EM ±9.4%Jul 15 — IV 136% · EM ±8.1%Jul 16 — IV 260% · EM ±10.9%Jul 20 — IV 114% · EM ±26.8%Jul 21 — IV 108% · EM ±25.0%Jul 22 — IV 102% · EM ±23.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,162.23-0.1%
JNJ
Johnson & Johnson
$601.7B $255.02-0.2%
ABBV
AbbVie Inc.
$447.7B $256.20+1.1%
MRK
Merck & Company, Inc.
$307.2B $127.47-0.0%
PM
Philip Morris International Inc
$300.4B $195.00+0.3%
NVS
Novartis AG
$293.4B $152.73-0.2%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in